News
UCB's ongoing commitment to advancing research for people living with epilepsiesData include an open-label extension study describing the long-term safety of FINTEPLA®â–¼ (fenfluramine)[1] and global ...
26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies Data provide insights on developmental and ...
BRUSSELS, Aug. 29, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced it will present 26 abstracts from its epilepsy portfolio at the International Epilepsy Congress (IEC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback